XFRA
AC6
Market cap97mUSD
, Last price
EUR
Name
AlzeCure Pharma AB
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
20.65%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-48m
L+35.25%
CFO
-35m
L-1.51%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.
Key people
Martin Jonsson
Chief Executive Officer · since 2020
Birgitta Lundvik
Chief Financial Officer · since 2018
Johan Sandin
Chief Scientific Officer · since 2020
Pontus Forsell
Head of Research and Discovery · since 2019
Marta Segerdahl
Head of Development · since 2021
Janet Hoogstraate
Director · since 2024
Jan Lundberg
Director · since 2024
Thomas Pollare
Chairman of the Board · since 2017
Eva Lilienberg
Independent Director · since 2021
Independent Director · since 2017
Headquarters & legal address
Hälsovägen 7
Huddinge, AB 141 57
SE
Huddinge, AB 141 57
SE
Address
Halsovagen 7
Huddinge, AB 141 57
SE
Huddinge, AB 141 57
SE
Previous name
Goldcup 14140 AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||